Advanced Oncotherapy Plc (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, announced today that, in September 2016, it commenced discussions concerning a proposal it had received from a potential strategic partner that involves, inter alia, non-dilutive financing arrangements, which were mentioned in the announcement of 30 September 2016. Discussions with this potential partner are continuing and their scope has been expanded. The Company will keep the market informed of any developments accordingly.
Advanced Oncotherapy Plc is a provider of particle therapy with protons that harnesses the best in modern technology. AVO’s team “ADAM”, based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.
